spacer
home > pmps > spring 2007 > outsourcing – know the risks
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Outsourcing – Know the Risks

Although it remains a growing trend, Juval Aviv of Interfor assesses the potentially harmful risks associated with outsourcing and the impact they could have on the pharmaceutical industry

Outsourced manufacturing has continued to grow exponentially over the past 20 years, becoming the standard business model for the pharmaceutical industry. At first, these companies provided access to resources not available internally or to additional resources during peak times. Today, however, outsourced manufacturing is a given. It is estimated that the US market for outsourced manufacturing is growing at the rate of 10 to 12 per cent annually, with many companies even outsourcing sales, data processing and computer operations. Smaller companies couldn’t exist without it and even larger, more established companies have turned to outsourced manufacturing to improve the bottom line.

RISK FROM COUNTERFEITERS

Before outsourcing is even considered, you have to be aware that you will be exposing your supply chain to tremendous risk from counterfeiters. Counterfeiting is a considerable and growing problem for the pharmaceutical industry and a danger to the public. Whether or not you choose to outsource, counterfeiting is a problem for every pharmaceutical company. However, sharing product information with third parties obviously increases the risks dramatically.

It is often incorrectly assumed that counterfeit pharmaceuticals are predominantly a problem for developing countries. However, with soaring healthcare costs and the increasing ease of purchasing pharmaceuticals online without a prescription, the problem is reaching countries with developed drug policies and regulations – including the US and the UK. Internet sales are a particular problem as most of the drugs come from unauthorised secondary wholesalers, selling products from counterfeiting hotspots such as Mexico, China and India.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Juval Aviv holds an MA in Business from Tel Aviv University and is President and CEO of Interfor, Inc. Before founding Interfor, Juval served as an officer in the Israel Defense Force, leading an elite Commando/Intelligence Unit, and was later selected by the Israeli Secret Service (Mossad) to participate in a number of intelligence and special operations in many countries in the late 1960s and 1970s. He has personally solved numerous cases of fraud, illegal short-selling, embezzlement and anti-competitive behaviour. Juval is the author of Staying Safe: The Complete Guide to Protecting Yourself, Your Family, and Your Business, 2004. He has also been a frequent contributor to articles and programmes on US preparedness relative to various forms of terrorism. Additionally, Juval serves as a consultant on counterterrorism for the FOX News Channel and has appeared on ABC’s ‘Nightline’, CNN, MSNBC and in numerous national and international newspapers and magazines.
spacer
Juval Aviv
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Francine Lane Recipient of 2019 DIA Global Inspire Award

JERSEY CITY – March 21, 2019 – Francine Lane, TrialScope Vice President of Global Transparency, has received a 2019 Global Inspire Award from the Drug Information Association (DIA). Lane, chair of the DIA’s Clinical Trial Disclosure Community, and Robert Paarlberg, past chair, are co-recipients of the Community Engagement Award. The award recognizes DIA community chairs for consistently driving engagement while advancing knowledge and thought leadership within their membership communities.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement